Business
Annual Report & Financial Statements - 31 Dec 2022
Annual Report & Financial Statements - 31 Dec 2022.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\n \nAnnual Report & Financial Statements - 31 Dec 2022\nFoundation & team in place to deliver key R&D and commercial milestones\nRoquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, announces its audited results for year ended 31 December 2022.\nCopies of the Annual Report and Financial Statements will be made available on the Company's website at: https://www.roquefortplc.com/results-centre\nHighlights\n· Acquisition of Oncogeni in September 2022 through the issue of 50,000,000 new ordinary shares in the Company, together with successful Placing raising gross proceeds of £1,015,000\n· Further strengthened Board and senior management team through the appointment of Ajan Reginald as CEO, Professor Sir Martin Evans as Chief Scientific Officer and Dr Darrin Disley as Non-Executive Director\n· Reinforced the Company's foundation through Oncogeni's state of the art laboratory located in Stratford-upon-Avon which has the infrastructure required for the pre-clinical development of the Group's portfolio of antibodies, oligonucleotides and cell and gene therapies - significant cost advantages\n· Cash at year end 31 December 2022 of £2,322,974\nPre-clinical highlights\n· Acquisition of Oncogeni significantly increased pre-clinical portfolio to four fully funded pre-clinical drug development programs providing multiple opportunities for success\n· Highly synergistic programs focused on the pre-clinical development of the Midkine antibodies, Midkine RNA, MK Cell Therapies and STAT-6, siRNA\n· Signed partnership agreements and commenced pre-clinical development programs with leading academic cancer research centres\nPost Period End Highlights\n· Key milestone achieved with ROQ-A1 and ROQ-A2 Midkine antibody programs, targeting metastatic breast cancer, and lung and liver metastasis, successfully demonstrated in vivo safety in pre-clinical development programs and progressed into in vivo efficacy studies\n· siRNA, MK cell therapy and Midkine oligon...